47196
document
Alinidine in chronic stable angina : the effect on diastolic perfusion time . The present study has been performed to assess the effects of alinidine on diastolic duration during exercise in chronic coronary artery disease . Twelve male patients with stable effort angina and without previous myocardial infarction were studied . They received alinidine or placebo in a double-blind randomized crossover trial for 3 days after a wash-out period of 4 days . Alinidine was administered at a dosage of 30 mg 3 times a day . At the end of each treatment the patients underwent upright bicycle exercise . Left ventricular time intervals were obtained by means of carotid thermistor plethysmography . Diastolic duration was calculated by subtracting the electromechanical systole from the R-R interval and expressed as a percentage of the cardiac cycle ( % D ) . Alinidine increased both total exercise duration from 246.7 +/- 120.7 to 346.6 +/- 114.1 s ( p less than 0.05 ) and time to 0.1-mV ST segment depression from 98.3 +/- 53 to 187.2 +/- 105 s ( p less than 0.05 ) . Similarly the drug induced a reduction of the rate-pressure product and of the extent of ischemic ST segment depression during exercise . % D was increased by alinidine both at rest and during exercise . A direct linear regression between R-R and % D was found after both alinidine and placebo treatments either at rest or during exercise . Nevertheless , no difference was observed between both slopes and intercepts . Therefore , since the relationship between R-R interval and % D was unaffected by alinidine , it was possible to hypothesize that the changes in diastolic duration were due only to the bradycardic action of the drug .
47197
Intervention_Pharmacological
Alinidine
47198
Intervention_Pharmacological
alinidine
47199
Intervention_Pharmacological
alinidine
47200
Intervention_Control
placebo
47201
Intervention_Pharmacological
Alinidine
47202
Intervention_Physical
upright bicycle exercise
47203
Intervention_Pharmacological
Alinidine
47204
Intervention_Pharmacological
alinidine
47205
Intervention_Control
placebo
47206
Intervention_Pharmacological
alinidine
47207
Outcome_Physical
diastolic perfusion time .
47208
Outcome_Physical
ventricular
47209
Outcome_Physical
obtained
47210
Outcome_Physical
Diastolic duration
47211
Outcome_Other
calculated by subtracting the electromechanical systole from the R-R interval and expressed as a percentage of the cardiac cycle ( % D ) .
47212
Outcome_Physical
induced a reduction of the rate-pressure product
47213
Outcome_Physical
linear regression
47214
Outcome_Other
diastolic duration
47215
Participant_Condition
chronic stable angina
47216
Participant_Condition
chronic coronary artery disease
47217
Participant_Sample-size
Twelve
47218
Participant_Sex
male
47219
Participant_Condition
stable effort angina
47220
Participant_Condition
myocardial infarction